Skip to main content
padlock icon - secure page this page is secure

Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid

Buy Article:

$43.00 + tax (Refund Policy)


The optimal management of menorrhagia among women with abnormal laboratory haemostasis is uncertain. In a crossover study, 116 women with menorrhagia [pictorial blood assessment chart (PBAC) score >100], negative gynaecological evaluation and abnormal laboratory haemostasis were randomly assigned to either intranasal desmopressin (IN-DDAVP) or tranexamic acid (TA) therapy for two menstrual cycles. The subjects then crossed over to the second study drug for two additional cycles. Menstrual blood loss (MBL) was measured by PBAC scores at baseline and after each menstrual cycle. Quality of life (QOL) was assessed with four validated instruments. There was a statistically significant decrease in PBAC scores for both treatments. On average, the estimated decrease in the PBAC from baseline was −64·1 [95% confidence interval (CI) = −88·0, −40·3] for IN-DDAVP and −105·7 (95% CI = −130·5, −81·0) for TA. The decrease in PBAC score was greater for TA than IN-DDAVP (a difference of 41·6, P-value = 0·0002, 95% CI = 19·6, 63·6). The test for treatment-type effect was significant (P < 0·0001) suggesting a greater reduction in PBAC score with TA. Use of both IN-DDAVP and TA improved QOL by all four instruments. We conclude that both medications reduced MBL and improved QOL among females with menorrhagia and abnormal laboratory haemostasis, but TA proved more effective.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: intranasal desmopressin; menorrhagia; quality of life; tranexamic acid

Document Type: Research Article

Affiliations: 1: Mary M. Gooley Hemophilia Center and the Rochester General Hospital, Rochester, NY 2: Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 3: Robert Wood Johnson Medical School, New Brunswick, NJ 4: Emory University School of Medicine, Atlanta, GA 5: Mayo Clinic, Rochester, MN 6: Duke University, Durham, NC 7: Michigan State University, East Lansing, MI, USA

Publication date: 01 April 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more